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use of the widely-prescribed diabetes drug metformin with reduced
cancer incidence and mortality has prompted a great deal of ongoing
preclinical and clinical investigation of the drug's apparent anticancer
effect.(Quinn et al., 2013)
Sarcomas are rare tumors of mesenchymal origin, encompassing
over 70 histological subtypes of distinct clinical behavior and underlying
biology. Metastatic disease is common and associatedwith poor progno-
sis. Diverse molecular pathology and, in many cases, lack of effective
systemic therapies indicate a compelling case for drug repurposing
studies in sarcoma. The characterization of recurrent mutations of cKITThe exploration and identiﬁcation of new anti-cancer therapeutic
indications for an approved drug already in use, or for a drug that was
shelved for non-safety reasons in early clinical development, represents
an attractive alternative to the costly, time-consuming and inefﬁcient
process of developing novel anticancer agents. Drug repositioning or
repurposing can bypass the discovery and early clinical phases of cancer
drug development, potentially reducing the hundreds of millions of
dollars and more than a decade typically required to see a novel agent
through to regulatory approval. Incidental clinical observations, case–
control analysis of large populations and modern high-throughput
drug screening techniques have been employed in identifying agents
with hitherto undiscovered or ignored biological activity that could
underpin effective anticancer activity.
To date, themost signiﬁcant example of drug repositioning in oncol-
ogy has seen thalidomide and its analog lenalidomide approved for the
treatment of multiple myeloma.(Engelhardt et al., 2014) Notoriously
developed as a sedative and anti-emetic in the 1950s, thalidomide
was decades later seen to have anti-angiogenic effects in animalmodels,
research that translated into signiﬁcant clinical activity in myeloma,
acute myeloid leukemia and myelodysplastic syndrome. Large scale
prospective studies of aspirin chemoprophylaxis in the primary or
secondary prevention of several common cancers are underway with
the goal of conﬁrming recurring evidence of effect detected by retro-
spective analysis of large cardiovascular study cohorts (Rothwell et al.,om.2016.02.026.
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. This is an open access article underin gastrointestinal stromal tumors (GIST) and TSC1/2 in malignant
peripheral epithelioid cell tumors (PEComa) formed the basis for the
respective repurposing of imatinib and sirolimus. Imatinib, a small
molecule inhibitor originally developed to target BCR-ABL in chronic
myeloid leukemia but whose kinase inhibition extends to cKIT, has
dramatically improved survival outcomes in both early-stage and
advanced GIST,(Rajendra et al., 2013) whilst unprecedented response
rateswere seen in PEComa in case series treatedwith sirolimus, an inhib-
itor of the mTOR complex used in the prevention of organ transplant
rejection.(Benson et al., 2014)
Propranolol has been successfully repurposed for the treatment of
infantile hemangioma, based on a number of initial clinical observations
and a subsequent randomized trial.(Léauté-Labrèze et al., 2015)
Furthermore, a number of pre-clinical and clinical studies have indicat-
ed that beta-blockade may have a potential therapeutic role in the
management of various cancers, including angiosarcoma.(Chow et al.,
2015) Pasquier and colleagues previously demonstrated that the addi-
tion of beta blocker enhanced anti-proliferative and anti-angiogenic
effects of co-administered cytotoxics in animal models of breast cancer
and neuroblastoma.(Pasquier et al., 2011; Pasquier et al., 2013) In this
issue of EBioMedicine, they now describe their retrospective evaluation
of a combination of propranolol and vinblastine-based chemotherapy
in a small series of patients with metastatic angiosarcoma.(Pasquier
et al., 2016) These data, although retrospective and provisional, are
worthy of further prospective evaluation and highlight the possibility
of drug re-positioning in rare tumors such as sarcoma. The Food and
Drug Administration orphan drug designation was proposed as a
means to reduce the development costs of therapy in rare diseases
(b200,000 patients in the United States), and this may be an avenue
for drug repositioning. Vigilant clinical observation and reporting inthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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burgeoning understanding of sarcoma molecular pathology can be
employed to hopefully identify drugs that are candidates for reposi-
tioning studies.
The study raises a number of relevant questions regarding research
and drug development in rare cancers. Obtaining access to drugs such
as propranolol for a small number of patients is relatively easy, but
performing a randomized trial in a very rare and heterogeneous entity
such as angiosarcoma is a considerableﬁnancial and logistical challenge.
Large international multicenter studies are required to achieve sufﬁcient
recruitment, a considerable undertaking that pharmaceutical companies
are unlikely to consider due to the lack of return from generically avail-
able products. There is, however, a strong track record of investigator-
initiated trials within the international sarcoma community. The funding
of such trials by funding agencies or charities may be limited, as such
projects may be deemed less exciting or innovative compared with
other studies evaluating a novel agent. In addition, drug repositioning
is not risk free, and involves the use of a drug in a newpatient population
with potentially differing pathophysiological characteristics and also
new drug formulations and dosing schedules.
In conclusion, the study by Pasquier and colleagues is of interest and
should be explored further in a prospective trial. Drug repositioning
could potentially be of beneﬁt in other sarcoma subtypes particularly
those with currently no effective systemic therapy. Such an approach
clearly requires collaboration between basic, translational and clinical
researchers.Disclosure
The authors declared no conﬂicts of interest.
References
Engelhardt, M., et al., 2014. European myeloma network recommendations on the
evaluation and treatment of newly diagnosed patients with multiple myeloma.
Haematologica 99, 232–242.
Rothwell, P.M., et al., 2011. Effect of daily aspirin on long-term risk of death due to cancer:
analysis of individual patient data from randomised trials. Lancet Lond. Engl. 377, 31–41.
Quinn, B.J., Kitagawa, H., Memmott, R.M., Gills, J.J., Dennis, P.A., 2013. Repositioning
metformin for cancer prevention and treatment. Trends Endocrinol. Metab. 24,
469–480.
Rajendra, R., Pollack, S.M., Jones, R.L., 2013. Management of gastrointestinal stromal
tumors. Future Oncol. 9, 193–206.
Benson, C., et al., 2014. A retrospective study of patients withmalignant PEComa receiving
treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience.
Anticancer Res. 34, 3663–3668.
Léauté-Labrèze, C., et al., 2015. A randomized, controlled trial of oral propranolol in
infantile hemangioma. N. Engl. J. Med. 372, 735–746.
Chow, W., et al., 2015. Growth attenuation of cutaneous angiosarcoma with propranolol-
mediated β-blockade. JAMA Dermatol. 151, 1226–1229.
Pasquier, E., et al., 2011. Propranolol potentiates the anti-angiogenic effects and anti-
tumor efﬁcacy of chemotherapy agents: implication in breast cancer treatment.
Oncotarget 2, 797–809.
Pasquier, E., et al., 2013. β-blockers increase response to chemotherapy via direct
antitumour and anti-angiogenic mechanisms in neuroblastoma. Br. J. Cancer 108,
2485–2494.
Pasquier, E., et al., 2016. Effectivemanagement of advanced angiosarcoma by the synergistic
combination of propranolol and vinblastine-basedmetronomic chemotherapy: a bench
to bedside study. EBioMedicine 6, 87–95.
